Rallybio Corporation ( (RLYB) ) has released its Q3 earnings. Here is a breakdown of the information Rallybio Corporation presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rallybio Corporation is a clinical-stage biotechnology company focused on developing transformative therapies for rare diseases, particularly in the areas of complement dysregulation and hematology.
In its third-quarter 2025 earnings report, Rallybio Corporation highlighted significant progress in its lead program, RLYB116, and financial improvements, including a notable cash influx from the sale of its interest in REV102.
Key financial metrics for the quarter include a net income of $16.0 million, a significant improvement from a net loss of $11.5 million in the same period last year. This positive shift was largely driven by a $20 million gain from the sale of interest in REV102. Additionally, the company reported a decrease in both R&D and G&A expenses, reflecting strategic cost management and workforce reductions. Rallybio’s cash position remains strong, with a runway extended through 2027.
Strategically, Rallybio is advancing its RLYB116 program, having completed dosing in Cohort 1 of its Phase 1 study, with data expected in the fourth quarter of 2025. The company is also evaluating future development plans for RLYB332, aimed at treating diseases of iron overload.
Looking ahead, Rallybio remains focused on advancing its pipeline and achieving key clinical milestones, with management expressing confidence in the potential of RLYB116 to address unmet medical needs in complement-mediated diseases.